{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:43:36Z","timestamp":1791333816763,"version":"4.3.1"},"reference-count":18,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Allergy and Infectious Disease, NIH, USA","award":["HHSN272201700041I"],"award-info":[{"award-number":["HHSN272201700041I"]}]},{"name":"National Institute of Allergy and Infectious Disease, NIH, USA","award":["A51"],"award-info":[{"award-number":["A51"]}]},{"name":"National Institute of Allergy and Infectious Disease, NIH, USA","award":["A91"],"award-info":[{"award-number":["A91"]}]},{"name":"National Institute of Allergy and Infectious Disease, NIH, USA","award":["75N93019D00021"],"award-info":[{"award-number":["75N93019D00021"]}]},{"name":"National Institute of Allergy and Infectious Disease, NIH, USA","award":["75N93023F00004"],"award-info":[{"award-number":["75N93023F00004"]}]},{"name":"National Institute of Allergy and Infectious Disease, NIH, USA","award":["B21"],"award-info":[{"award-number":["B21"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Yellow fever virus (YFV) recurrently causes severe outbreaks in tropical regions of South America and Africa and an average of 30 to 40 thousand deaths worldwide each year. An effective vaccine is available but the coverage of the population in countries at risk is not optimal. No antivirals are currently approved for YFV treatment. Herein, we describe the evaluation of 6-MMPr, a de-novo-purine-nucleotide biosynthesis inhibitor, as a potentiator for enhanced activity of the broad-spectrum antiviral drug favipiravir in a hamster model of yellow fever. Administration of 6-MMPr was well-tolerated and a combination of favipiravir and 6-MMPr did not cause overt toxicity as indicated by normal weight gain of treated hamsters. Treatment with a combination of a suboptimal dose of favipiravir with 6-MMPr was significantly more effective in improving survival, weight change and virus replication when compared with monotherapy. The initiation of treatment two days after virus challenge was also effective in improving survival when compared with monotherapy. Our results demonstrate the safety and efficacy of such a combination either as a preventive or delayed treatment.<\/jats:p>","DOI":"10.3390\/pathogens14090925","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T08:56:46Z","timestamp":1758013006000},"page":"925","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In Vivo Efficacy of a Broad-Spectrum Antiviral Combination Against Yellow Fever in a Hamster Model"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8720-1304","authenticated-orcid":false,"given":"Abbie E.","family":"Weight","sequence":"first","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter","family":"Stanger","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0560-6509","authenticated-orcid":false,"given":"Robert J.","family":"Geraghty","sequence":"additional","affiliation":[{"name":"Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4970-8822","authenticated-orcid":false,"given":"Laurent F.","family":"Bonnac","sequence":"additional","affiliation":[{"name":"Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin G.","family":"Julander","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.01074-08","article-title":"Activity of T-705 in a Hamster Model of Yellow Fever Virus Infection in Comparison with That of a Chemically Related Compound, T-1106","volume":"53","author":"Julander","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of Action of T-705 against Influenza Virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.antiviral.2008.07.009","article-title":"Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents","volume":"80","author":"Morrey","year":"2008","journal-title":"Antivir. Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Nguyen, T.H.T., Guedj, J., Anglaret, X., Laou\u00e9nan, C., Madelain, V., Taburet, A.-M., Baize, S., Sissoko, D., Pastorino, B., and Rodallec, A. (2017). Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005389"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sissoko, D., Laouenan, C., Folkesson, E., M\u2019lEbing, A.-B., Beavogui, A.-H., Baize, S., Camara, A.-M., Maes, P., Shepherd, S., and Danel, C. (2016). Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002066"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hassanipour, S., Arab-Zozani, M., Amani, B., Heidarzad, F., Fathalipour, M., and Martinez-De-Hoyo, R. (2021). The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-90551-6"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1093\/infdis\/jiad409","article-title":"Oral Favipiravir Exposure and Pharmacodynamic Effects in Adult Outpatients With Acute Influenza","volume":"230","author":"Hayden","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1124\/mol.113.087247","article-title":"Role of Human Hypoxanthine Guanine Phosphoribosyltransferase in Activation of the Antiviral Agent T-705 (Favipiravir)","volume":"84","author":"Naesens","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Soto-Acosta, R., Edwards, T.C., Dreis, C.D., Krishna, V.D., Cheeran, M.C.-J., Qiu, L., Xie, J., Bonnac, L.F., and Geraghty, R.J. (2021). Enhancing the Antiviral Potency of Nucleobases for Potential Broad-Spectrum Antiviral Therapies. Viruses, 13.","DOI":"10.3390\/v13122508"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/0006-2952(69)90069-0","article-title":"Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides","volume":"18","author":"Tay","year":"1969","journal-title":"Biochem. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.crohns.2011.07.009","article-title":"Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment","volume":"6","author":"Seinen","year":"2012","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mendenhall, M., Russell, A., Smee, D.F., Hall, J.O., Skirpstunas, R., Furuta, Y., Gowen, B.B., and Bausch, D.G. (2011). Effective Oral Favipiravir (T-705) Therapy Initiated after the Onset of Clinical Disease in a Model of Arenavirus Hemorrhagic Fever. PLoS Negl. Trop. Dis., 5.","DOI":"10.1371\/journal.pntd.0001342"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Thaker, S.K., Ch\u2019Ng, J., and Christofk, H.R. (2019). Viral hijacking of cellular metabolism. BMC Biol., 17.","DOI":"10.1186\/s12915-019-0678-9"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1099\/vir.0.83381-0","article-title":"Thiopurines inhibit bovine viral diarrhea virus production in a thiopurine methyltransferase-dependent manner","volume":"89","author":"Hoover","year":"2008","journal-title":"J. Gen. Virol."},{"key":"ref_17","first-page":"1","article-title":"6-methylmercaptopurine riboside, a thiopurine nucleoside with antiviral activity against canine distemper virus in vitro","volume":"14","author":"Tozato","year":"2017","journal-title":"Virol. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ijantimicag.2017.08.016","article-title":"The thiopurine nucleoside analogue 6-methylmercaptopurine riboside (6MMPr) effectively blocks Zika virus replication","volume":"50","author":"Franca","year":"2017","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/9\/925\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:44:58Z","timestamp":1760035498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/9\/925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["pathogens14090925"],"URL":"https:\/\/doi.org\/10.3390\/pathogens14090925","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]}}}